NeOnc reports 12.5% response rate in updated Phase 2a NEO100 glioma trial

PUBT · 21h ago
NeOnc reports 12.5% response rate in updated Phase 2a NEO100 glioma trial
  • NeOnc reported updated Phase 2a results showing an additional partial response to intranasal NEO100 in recurrent or progressive high-grade glioma.
  • The findings improve on topline results released Aug. 12, 2026; most patients experienced tumor shrinkage or stable disease.
  • Reported treatment-related side effects were mild or moderate, with no treatment-related serious adverse events or treatment discontinuations.
  • The trial lacked a randomized control group, limiting comparisons with other treatments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170800PRIMZONEFULLFEED9879203) on November 17, 2026, and is solely responsible for the information contained therein.